# Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

- Link: https://www.directorstalkinterviews.com/nuformix-plc-nxp002-data-strengthens-path-towards-toxicology-and-partnering-video/4121260848
- Published: 2026-08-21T07:10:18+01:00
- Author: Ethan Davis

**Nuformix Plc**‘s ([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l))
latest NXP002 preclinical results have given the company important new evidence 
as it looks to advance its inhaled treatment for idiopathic pulmonary fibrosis. 
Executive Director Dr Dan Gooding explains how the study demonstrated therapeutically
relevant drug concentrations in the lung alongside fibrosis-related pathway engagement,
why the findings support the potential therapeutic window for NXP002 and how the
data can now help shape the programme’s next toxicology studies. He also discusses
ongoing target-identification work, the company’s funding position and why upcoming
meetings with prospective pharma partners at the European Respiratory Society Congress
in Barcelona could be an important next step.

### Key Moments

**00:32 — Why NXP002 is targeting a major IPF treatment gap**
**01:40 — The rationale
for inhaled delivery****03:25 — Therapeutically relevant lung exposure demonstrated****
05:17 — Data opens the way to the next development step****06:05 — What prospective
pharma partners want to see****07:20 — Target-identification work gathers pace****
09:21 — Nuformix outlines its funding position****09:43 — Toxicology planning and
target discovery move forward****11:08 — Barcelona puts partnering discussions centre
stage****11:31 — Existing and new pharma conversations continue**

Nuformix is a pharmaceutical development company focused on developing new formulations
of existing drugs for areas of unmet medical need. Its lead programme, NXP002, is
being developed as an inhaled treatment for fibrotic lung diseases including idiopathic
pulmonary fibrosis, with the company working towards further preclinical development
and potential partnering opportunities.

Share on:
